ALVIO.PA Valerio Therapeutics

Healthcare Biotechnology Euronext Paris
0.4700 EUR
Close of Nov 6, 2026
0.1025 0.9800
Market cap
EUR 276M
P/E
-
P/B
91.71x
ROE
-
Dividend yield
-
Fundamental score
1.0/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is ALVIO.PA undervalued?

Graham number

The Graham number of Valerio Therapeutics cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Valerio Therapeutics fundamental analysis

2 of 11 checks passed

ROE 0/2

The stock's ROE indicates a negative return (-70.86%) on shareholders' equity, suggesting poor financial performance.

ROA 0/2

The stock's ROA (-87.51%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

PBV 2/2

The stock's low PBV ratio (0x) suggests it's undervalued, making it an attractive opportunity for investors.

DER 2/2

The stock has a minimal amount of debt (45%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

Revenue Growth 0/2

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

Net Profit Growth 0/2

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

Assets Growth 0/2

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

Graham Number 0/1

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

Dividend Growth 0/2

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

Dividend 0/2

The company's lack of dividends in the past three years may concern investors seeking regular income.

Buffet Intrinsic Value 0/1

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Valerio Therapeutics stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Valerio Therapeutics

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, develops technology platforms dedicated to the targeted delivery of therapies. The company develops PlatON, a proprietary chemical platform for DNA decoy therapies, which generates new compounds and broadens its product portfolio; DecoyTAC, a mechanism of action of DNA decoy therapies coupled with targeted protein degradation; and V-body platform, a bispecific T-cell engagers, antibody" drug conjug…

Full company profile